Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences

Fate Therapeutics (NASDAQ: FATE) said management will participate in five investor conferences in Q2 2026 with scheduled dates and locations listed below.

Rhea-AI Summary

Fate Therapeutics (NASDAQ: FATE) said management will participate in five investor conferences in Q2 2026 with scheduled dates and locations listed below.

• April 14 — Needham Virtual Healthcare Conference (virtual)
• May 13 — Bank of America Healthcare Conference, Las Vegas
• May 19 — H.C. Wainwright BioConnect, New York
• June 4 — Jefferies Global Healthcare, New York
• June 10 — Goldman Sachs Global Healthcare, Miami Beach

The company said presentations or fireside chats may occur and live webcasts will be available under Events & Presentations on the company website, with archived replays accessible for 30 days.

Argus Apr 9 session

+7.63% close to close Open Argus

Details

News Market Reaction – FATE

In the Apr 9 session, FATE gained 7.63%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +7.6% in the session following this news. A strong positive reaction aligns with how...

Analysis

The stock moved +7.6% in the session following this news. A strong positive reaction aligns with how Fate’s stock previously responded to visibility events such as the Leerink conference and the 2025 results, which saw moves above 5%. This type of multi-conference announcement mainly increases investor engagement rather than altering fundamentals. Investors have also seen recent insider sell-to-cover activity and equity grants, which can temper enthusiasm if momentum fades.

Key Figures

Number of conferences: 5 conferences Needham conference date: April 14 BofA conference date: May 13 +4 more

Number of conferences

5 conferences

Investor events in Q2 2026

Needham conference date

April 14

25th Annual Needham Virtual Healthcare Conference 2026

BofA conference date

May 13

Bank of America Healthcare Conference 2026 in Las Vegas, NV

H.C. Wainwright date

May 19

4th Annual BioConnect Investor Conference in New York, NY

Jefferies conference date

June 4

2026 Jefferies Global Healthcare Conference in New York, NY

Goldman Sachs conference date

June 10

47th Annual Global Healthcare Conference in Miami Beach, FL

Webcast replay period

30 days

Archived replay availability after each conference webcast

Historical Context

5 past events · Latest: Apr 02

5 events

1. Apr 02

   Inducement RSU grant

   24h Move

   -2.5%

   Single new-hire award of 7,260 RSUs vesting over four years.

2. Mar 04

   Inducement RSU grants

   24h Move

   -4.8%

   Three new hires granted 50,700 RSUs with four-year vesting schedule.

3. Mar 03

   Conference participation

   24h Move

   +5.8%

   Announcement of participation and fireside chat at Leerink healthcare conference.

4. Feb 26

   Earnings and updates

   24h Move

   +5.4%

   Reported 2025 financials, $205.1M cash, program progress, and lower expenses.

5. Feb 03

   Inducement awards

   24h Move

   -0.9%

   New employee options and RSUs totaling 210,000 shares with staged vesting.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

induced pluripotent stem cell (iPSC), cellular immunotherapies

2 terms

induced pluripotent stem cell (iPSC) medical

"a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular"

Induced pluripotent stem cells (iPSCs) are adult cells that scientists have reprogrammed to behave like embryonic stem cells, able to develop into many different cell types. Think of them as retrained workers who can be reassigned to multiple jobs; for investors they matter because iPSCs enable development of new therapies, personalized drug testing, and scaled cell products, which can drive long-term value but also face lengthy development timelines and regulatory scrutiny.

cellular immunotherapies medical

"iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune"

Cellular immunotherapies are medical treatments that use living immune cells, taken from a patient or donor and then trained, modified, or expanded in a lab so they better recognize and attack disease, such as cancer or infection. For investors, these therapies matter because they can offer dramatic, durable patient responses and premium pricing but also carry high development, manufacturing and regulatory risks—think of them as highly trained sniffer dogs that can be powerful but expensive and complex to deploy.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, April 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in five upcoming investor conferences in the second quarter of 2026.

25^th Annual Needham Virtual Healthcare Conference

Location: Virtual

Date: April 14^th  

Bank of America Healthcare Conference 2026

Location: Encore at the Wynn - Las Vegas, NV        

Date: May 13^th

H.C. Wainwright 4^th Annual BioConnect Investor Conference 

Location: Nasdaq - New York, NY        

Date: May 19^th

2026 Jeffries Global Healthcare Conference

Location: Marriott Marquis - New York, NY

Date: June 4^th

Goldman Sachs 47^th Annual Global Healthcare Conference

Location: Loews Miami Beach Hotel - Miami Beach, FL

Date: June10^th

The Company may participate in a presentation or a fireside chat at these conferences. When available, a live webcast will be accessible under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. An archived replay of the webcast will be available for 30 days on the Company’s website following the event.

About Fate Therapeutics, Inc.

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:

Ryan Douglas
Fate Therapeutics, Inc.
IR@fatetherapeutics.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Fate Therapeutics (FATE) present at the Needham Virtual Healthcare Conference in 2026?

Fate Therapeutics is scheduled to participate on April 14, 2026. According to the company, the event is virtual and may include a presentation or fireside chat with a live webcast available.

How can investors watch Fate Therapeutics (FATE) presentations at Q2 2026 conferences?

Live webcasts will be accessible via the company’s investor site under Events & Presentations. According to the company, archived replays will be available on the website for 30 days after each event.

Which in-person conferences will Fate Therapeutics (FATE) attend in Q2 2026 and when?

Fate Therapeutics plans in-person participation at May 13 (Bank of America, Las Vegas), May 19 (H.C. Wainwright, New York), June 4 (Jefferies, New York), and June 10 (Goldman Sachs, Miami Beach). According to the company, formats may vary.

Will Fate Therapeutics (FATE) host a replay of its conference presentations and for how long?

Yes. An archived replay will be available on the company website for 30 days following each event. According to the company, replays will be posted under Events & Presentations when available.

What type of participation will Fate Therapeutics (FATE) have at the Q2 2026 investor events?

The company said participation may include a presentation or a fireside chat at the listed conferences. According to the company, the exact format and timing will be announced when available and webcasts provided where offered.